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multiple courses of TACE is difficult to ascertain since additional courses may be 
prescribed under a patient-specific treatment protocol or due to non-optimal 
tumor response. Nonetheless, mean survival after discontinuing TACE was 
relatively similar regardless of number of treatments received.  
 
PODIUM SESSION I:  
CONCEPTUAL PAPERS  
 
CP1  
ADJUSTING FOR INFLATION IN ECONOMIC EVALUATIONS OF HEALTH 
TECHNOLOGIES: ARE WE DOING IT WRONG?  
Paulden M 
University of Toronto, Toronto, ON, Canada  
OBJECTIVES: Economic evaluations of health technologies typically require 
consideration of costs incurred in future years. Conventionally, all costs are 
represented in ‘real terms’ by adjusting for inflation. Future costs are then 
discounted to account for time preference. Although much has been written on 
the practice of discounting, health economists have paid surprisingly little 
attention to the issue of appropriately adjusting for inflation. This paper argues 
that the conventional approach to adjusting for inflation in economic 
evaluations of health technologies is inappropriate. METHODS & RESULTS: The 
conventional approach follows the recommendations of the Washington Panel: 
costs must be converted to “constant dollars” using a single inflation rate 
representing the rate of “general price inflation”. However, “if the prices of the 
goods in question change at a rate different from general price levels, this 
variation should be reflected in the adjustment used”. Some analyses therefore 
use the ‘Medical Component’ of the Consumer Price Index (CPI), or an equivalent 
measure, rather than the headline rate. Critically, for the conventional approach 
to be appropriate requires that all costs change at the same rate over time. This 
is generally not the case – some costs may rise (e.g. pharmaceuticals) at the same 
time as other costs fall (e.g. personal computers). In particular, products losing 
patent protection may experience a sudden fall in price out-of-line with general 
price inflation. A solution is to assign each cost a unique time profile subject to 
specific market conditions. Rather than applying an inflation rate, future costs 
are instead estimated using a unique projection model for each cost. 
CONCLUSIONS: The conventional approach to adjusting for inflation is 
inappropriate. A solution is to estimate a unique time profile for each cost 
component. Models routinely used by financial analysts may provide an example 
for how this projection can be done in practice.  
 
CP2  
THE NOTION OF REPRESENTATIVE LANGUAGES IN THE CONTEXT OF 
TRANSLATABILITY ASSESSMENT  
Basse SJ, Martin ML, McCarrier KP 
Health Research Associates, Inc., Seattle, WA, USA  
BACKGROUND: While current best-practices in PRO development include 
evaluation of the relative ease of translation for global trial use prior to 
instrument finalization, methodologies for this translatability assessment (TA) 
vary greatly. In the proposed approach, representative languages (RLs) are 
selected to assess the translation difficulty of PRO concepts without the time and 
cost of evaluating multiple languages with shared characteristics. METHODS: In 
the genealogical approach employed by linguists, languages sharing a common 
ancestor that become separated by geographical or socio-political boundaries 
will evolve in distinct ways, resulting in sets of languages (families) with 
common linguistic features (e.g. word order, phrasal structure, morphology, 
lexical items, etc.). Because of this relative similarity within language groups, 
efficiency can be gained by assessing translatability with sets of appropriately-
selected representative languages, which can in turn predict translation 
problems likely to affect others in their linguistic families. As such, use of 
appropriate criteria for the selection the RLs is of key importance. RESULTS: 
Selection of RLs should be based both on linguistic properties and other features 
salient to outcomes research. A family or group of languages may also be defined 
by shared characteristics that are not purely linguistic in nature. Features such 
as geographic and cultural (religious/dietary/social) aspects, number and 
distribution of speakers worldwide, and criteria related to health care utilization 
or study implementation should be considered in the definition of language 
families/groups and in the selection of RLs. CONCLUSIONS: Despite differences 
that undeniably exist between individual languages, limited information can be 
gained by the repetitive assessment of prospective translation difficulty within 
groups of languages having similar characteristics. Instead, the use of a 
representative language to assess translation difficulty for a related group of 
languages provides greater resource efficiency and more effective application of 
TA in providing important feedback prior to finalization of newly developed 
measures.  
 
CP3  
PIECEWISE MODELING OF TIME-TO-EVENT DATA WITH FLEXIBLE 
PARAMETERIZATION OF COVARIATES AND EFFECTS  
Ishak KJ 
United BioSource Corporation, Dorval, QC, Canada  
Projection of time-to-event distributions is necessary to obtain accurate 
estimation of life expectancy, or prediction of event times for economic models. 
Parametric survival analysis techniques are typically used, and can represent a 
broad range of shapes. In some cases, however, the best distributional fit fails to 
capture the variation in hazards over the entire time span, or it provides 
acceptable fit to the data but yields clinically implausible projections (e.g., 
constant hazard of death). More flexible techniques, like piecewise exponential 
models, can overcome these issues but remain generally underused. In 
piecewise models, the time axis is divided into contiguous segments with a 
common parametric distribution assumed within each segment, but values of 
the parameters are allowed to vary. In addition to greater flexibility, this 
framework allows inclusion of time-dependent predictors and/or time-
dependent effects. Two important considerations are the number and placement 
of divisions on the time axis, and the choice of the common distribution. 
Examination of the cumulative and log-cumulative hazards plots can assist with 
these issues. For instance, the number/placement of divisions for a piecewise-
exponential model could be determined visually such that the points within 
each division of the cumulative hazard plot follow a linear pattern. The same can 
be done with log-cumulative hazard function for a piecewise-Weibull model. 
Although piecewise-exponential models can be made progressively more flexible 
by increasing the number of segments to capture even very complex patterns, 
the assumption of a constant hazard for the last segment can be limiting for 
projection. Thus, models based on Weibull distributions may be more 
appropriate, and possibly achieve similar fit with fewer segments. The 
subjectivity involved in these decisions can be minimized by using numeric 
optimizing strategies (e.g., grid search for placement of divisions) and use of fit 
statistics to select distributions.  
 
CP4  
MEASURING HEALTH OUTCOMES IN THE ABSENCE OF RIGOUR: WILLFUL 
IGNORANCE OR DELIBERATE MALPRACTICE?  
Kind P 
University of Leeds, Leeds, UK  
The evaluation of cost-effectiveness plays a central role in appraisal of new 
technologies undertaken by regulatory agencies across the world. As a 
consequence, health economists now play a critical part in generating the 
evidence base used to determine both access to and the price of treatment. No 
matter the complexity of any economic evaluation there is an inescapable need 
to describe and value the benefits of health care interventions. The computation 
of an ICER depends totally on the capacity to quantify marginal changes in 
health status. The orthodoxy adopted by most HTA agencies relies on the notion 
of capturing such outcomes via the use of generic health status measurement 
systems (for example HUI or EQ-5D) together with their corresponding social 
preference weights. The requirement that the values of the general population 
constitute the “correct” perspective is one element of the health economics 
credo. A second dictates that the “worth” of a health outcome shall be expressed 
in terms of utility – a concept that lacks a defined unit of measure or any agreed 
standard elicitation method. It is a regrettable fact that although health 
economists privately recognise the non-commensurability of Standard Gamble 
(SG) and Time Trade-Off (TTO) methods their public posture generally belies this 
contradiction. The status of the QALY as a useful metric of health benefit/loss 
has been fatally compromised by the failure of the scientific community to agree 
on a single method for determining the quality-adjustment factor. The 
preparedness of health economists to ignore this gap in their armamentarium 
runs counter to the rational practice of science. This paper challenges the 
intellectual deadweight of traditional health economics, specifically in regards to 
the measurement of health outcomes. Examples of defective practice drawn 
from Canadian and UK HTA reports will be used to illustrate the conceptual 
issues raised in this paper.  
 
PODIUM SESSION I:  
HEALTH CARE STUDIES – EXPENDITURE OR REIMBURSEMENT STUDIES  
 
HC1  
ORPHAN DISEASE DRUG COSTS IN THE UNITED STATES: ASSESSMENT OF 
LAUNCH PRICING TRENDS IN NON-CANCER ORPHAN DISEASES AND THE 
FUTURE IMPLICATIONS ON HEALTH SYSTEM ACCESS  
Davis EA1, Schwartz EL2 
1Metabolic Markets LLC, San Clemente, CA, USA, 2PriceSpective LLC, San Diego, CA, USA  
OBJECTIVES: With an increasing number of orphan disease (OD) drugs in 
development, the objective of the current study is to assess launch pricing trends 
of orphan drugs in the U.S. From this pricing assessment, implications and 
effects of increasing orphan drug prices on US managed care payer access is 
discussed. METHODS: Non-cancer OD approvals between 2003 and 2012 were 
extracted from the FDA Orphan Products database. Oncology and acute 
indications were excluded due to the confounders of acute and chronic 
treatments. Wholesale acquisition cost drug prices were collected from 
Medispan-PriceRx for product launch year. Annualized drug costs were 
calculated using the product label and consistent assumptions on weight-based 
dosing. Drug costs were adjusted to 2012 dollars using the CPI. RESULTS: From 
2003-2012, 33 ODs gaining U.S. market approval were included in the present 
analysis, with 30% of the drugs approved in 2011 and 2012. Launch pricing trends 
indicate that average launch price of ODs has increased 107% to $276,471/year 
during the examined time period. In 2012, 4 of 6 new ODs were priced between 
$294,000 and $295,000. CONCLUSIONS: The OD approvals and prices have grown 
substantially since 2003, accelerating in the last two years. The historically open 
US payer policy towards ODs must be reconsidered for sustainability. Expansion 
of the covered population will increase the traditionally modest payer OD 
economic burden, accelerated by new treatments. Payers must prepare by 
creating OD policy that identifies the most appropriate patients through 
collaboration with thought leaders and manufacturers. Payer investment should 
be made in patient management programs to ensure clinical benefit is delivered. 
The OD regulatory mechanism encourages manufacturers to invest modestly in 
clinical development and assign ultra-premium prices. Manufacturers may be 
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challenged by payers and regulatory authorities to develop evidence describing 
the burden of illness and justifying the payer investment.  
 
HC2  
HEALTH CARE EXPENDITURES AND DEPRESSION AMONG ADULTS WITH 
CANCER  
Pan X1, Sambamoorthi U2 
1West Virginia University, Morgantown, WV, USA, 2West Virginia University School of 
Pharmacy, Morgantown, WV, USA  
OBJECTIVES: Determine the relationship between health care expenditures and 
depression in individuals with cancer compared to those with cancer and 
depression, after controlling for demographic, socio-economic, access to care 
and other health status variables. METHODS: Cross-sectional data on 4766 adults 
from multiple years (2006, 2007, 2008, and 2009) of the nationally representative 
household survey, Medical Expenditure Panel Survey (MEPS) were used. Cancer 
and depression was identified from Medical conditions file. Dependent variables 
consisted of total, inpatient, outpatient, emergency room, prescription drugs and 
other expenditures. OLS on logged dollars and generalized linear models with 
log-link were performed. All analyses accounted for the complex survey design 
of the MEPS. RESULTS: Overall, 14% of individuals with cancer reported having 
depression. Among individuals with cancer and depression the average health 
care expenditures were $18,401compared to $12,091 among those without 
depression. After adjusting for demographic, socio-economic, access to care and 
other health status variables, those with depression had about 32% greater total 
expenditures compared to those without depression. Expenditures for every type 
were higher among individuals with depression compared to those without 
depression. Individuals with cancer and depression were more significantly 
more likely to use emergency rooms (AOR = 1.46) and prescription drugs (AOR = 
3.56) compared to their counterparts without depression. CONCLUSIONS: Among 
adults with cancer, those with depression had higher health care utilization and 
expenditures compared to those without depression. Policy efforts to reduce 
excess health care expenditures associated with depression may include 
screening for depressive symptoms and preventing major depression, timely 
depression treatment once depression is detected.  
 
HC3  
DISCREPANCIES BETWEEN FDA APPROVAL AND CMS COVERAGE FOR DRUGS 
AND DEVICES  
Chambers JD, Neumann PJ 
Tufts Medical Center, Boston, MA, USA  
OBJECTIVES: Following FDA approval, medical technology must still gain Centers 
for Medicare and Medicaid Services (CMS) coverage before Medicare 
reimbursement. However, the two agencies use approval processes based on 
different evidentiary standards. We identified the type and nature of 
discrepancies between FDA approval and CMS national coverage determinations 
(NCDs) for drugs and devices. METHODS: We used the Tufts Medical Center NCD 
database, which contains detailed information on 165 NCDs since 1999. For each 
device or Part B drug considered in an NCD (1999-2011) (n=69), we searched the 
FDA website to identify the approved indication. We classified CMS coverage as: 
more restrictive than FDA approval, i.e., conditions were placed on coverage 
beyond the FDA-approved label; equivalent to FDA approval; or less restrictive than 
FDA approval, i.e., CMS covers off-label indications. Further, we categorized 
conditions placed on CMS coverage as: “patient-related”, e.g., restricted to patients 
with certain comorbidities or characteristics; “place in therapy”, e.g., tied to use as 
second-line therapy; or “technology-related”, e.g., restricted to a particular 
application of the drug or device. RESULTS: CMS has covered FDA-approved 
drugs or devices taken through the Medicare NCD process in 80% of cases (55/69). 
For CMS covered drugs and devices (n=55), coverage was more restrictive in 32 
cases (58%), equivalent to FDA approval/clearance in 16 (29%), and less restrictive 
in seven (13%). Most common coverage restrictions were patient-related (78%), 
e.g., laparoscopic gastric banding to treat obesity is covered for patients suffering 
from an obesity-related comorbidity, and place in therapy (38%), e.g., coverage for 
extracorporeal immunoadsorption is covered for rheumatoid arthritis patients 
who have failed three disease-modifying antirheumatic drugs (DMARDs). In 
roughly one third of cases, CMS placed multiple restrictions on coverage. 
CONCLUSIONS: CMS coverage determinations are generally more restrictive 
than corresponding FDA approval. CMS often restricts coverage to patients with 
the most severe disease.  
 
HC4  
HOSPITALIZATION COSTS AND OUTCOMES AMONG ELDERLY CANCER 
PATIENTS IN THE UNITED STATES  
Khanna R1, Jariwala K2, Bentley JP1, Patel A3 
1University of Mississippi, University, MS, USA, 2University of Mississippi, Oxford, MS, USA, 
3Medical Marketing Economics, LLC, Oxford, MS, USA  
OBJECTIVES: To assess the patient-, hospital-, and discharge-level 
characteristics, and hospitalization rates among elderly patients with cancer in 
the United States (US). Hospitalization outcomes (length of stay [LOS], total 
charges, and mortality) among elderly patients with cancer were also studied. 
METHODS: A cross-sectional descriptive analysis of the 2009 Healthcare Cost 
and Utilization Project (HCUP) database was conducted. Patients were identified 
based on diagnosis (any-listed) of cancer using Clinical Classification Software 
(CCS). A control group of patients without cancer were identified by matching on 
age and gender (1:2 case-control). Analyses were conducted using PROC SURVEY 
procedures in SAS v9.2. RESULTS: In 2009, a total of 3,325,174 (weighted) 
hospitalizations occurred among elderly patients with cancer in the US. Elderly 
cancer patients had higher total hospital charges ($39,406 vs. $37,756), longer LOS 
(5.7 days vs. 5.4 days), and higher mortality (4.8% vs. 3.6%) as compared to those 
without cancer. A greater proportion of hospitalizations among cancer patients 
occurred in teaching hospitals (44.1% vs. 38.9%; p<0.001). In terms of location, a 
greater proportion of hospitalizations for cancer patients occurred in hospitals 
located in urban areas in comparison to those without cancer (88.1% vs. 84.7%; 
p<0.001). Total charges for hospitalizations among elderly patients with prostate 
(average LOS=4.9 days), lung (average LOS=6.1 days), and breast cancer (average 
LOS=4.9 days) were roughly $19.2, $16.1, and $16.0 billion, respectively. Mortality 
rates during hospitalization were the highest for those with pancreatic (10%), 
liver (9.7%), and lung cancer (8.7%). CONCLUSIONS: Elderly patients with cancer 
had significantly greater hospitalization burden as compared to those without 
cancer. Hospital mortality rates were the highest for elderly patients with 
pancreatic, liver, and lung cancer, respectively.  
 
PODIUM SESSION I:  
HEALTH TECHNOLOGY ASSESSMENT STUDIES  
 
HT1  
INTER-COUNTRY VARIABILITY IN COVERAGE DECISIONS FOR ORPHAN DRUGS: 
CRITERIA DRIVING HTA RECOMMENDATIONS IN SIX COUNTRIES  
Nicod E, Kanavos P 
London School of Economics and Political Science, London, UK  
Inter-country variability in access to orphan drugs across countries has been 
highlighted in a number of studies. Understanding the reasons driving coverage 
decisions is a way forward in identifying areas where HTA methods may be 
improved. OBJECTIVES: Objectives are three-fold: a) to establish a 
methodological framework enabling to systematically compare HTA processes 
across countries; b) to identify the criteria driving HTA recommendations for a 
sample of orphan drugs, and; c) to understand the reasons for diverging 
recommendations and propose ways to minimize these. METHODS: All common 
orphan drug-indication pairs appraised in six countries (England, Scotland, 
France, Sweden, Canada and Australia) between 2001 and 2012 were selected. 
Agreement levels in HTA outcomes between countries were measured using 
Cohen’s kappa scores. Thematic analysis, by creating an NVivo-9 coding manual, 
was conducted to systematically compare each compound. Reasons for diverging 
HTA outcomes were differentiated based on whether they are a consequence of 
country-specific considerations or of the HTA process, and ranked by frequency 
of occurrences. RESULTS: Fourteen orphan drug-indication pairs were retrieved. 
Agreement in HTA outcomes was poor (k = [-0.5; 0.3]). Eight drug-indication pairs 
appraised by at least four HTA bodies were analyzed, five of which received 
diverging outcomes. Preliminary results suggest that in four of five cases, 
reasons for diverging recommendations were a consequence of the HTA process. 
Examples of non-homogeneous assessments include: lack of appropriate 
primary endpoint, lack of long-term data, evidence not reflecting clinical 
practice, orphan status or unmet clinical need. CONCLUSIONS: Preliminary 
results identify the criteria driving the assessments and reasons why they result 
in diverging HTA outcomes, enabling a better understanding of these processes 
by elucidating the expectations and value judgments from HTA bodies, 
particularly on the orphan status, and identifying areas where more consensus 
on what constitutes appropriate HTA methodologies is needed. Final results will 
quantify these criteria in a systematic manner.  
 
HT2  
AGENCY AGREEMENT IN HEALTH TECHNOLOGY ASSESSMENT 
REIMBURSEMENT DECISIONS  
Jaksa A, Demb J, Ho YS, Daniel K 
Context Matters, Inc., New York, NY, USA  
OBJECTIVES: HTA agencies often review the same drugs for the same/similar 
indications. How often do agencies agree on their reimbursement decisions? 
Previous research has compared reimbursement recommendations (for the same 
drugs) for a limited number of agencies, but studies have rarely focused on more 
than 2 agencies. We collect and analyze a large number of health technology 
assessments from several countries to explore how often the agencies agree on 
their reimbursement decisions. METHODS: The data covered five agencies that 
make reimbursement decisions: NICE, SMC, PBAC, HAS and CADTH’s Common 
Drug Review. Our analysis only included decisions for drugs that were reviewed 
by at least two agencies. If a drug was reviewed multiple times by an agency for 
the same indication (i.e. resubmissions or updates) we used the most recent 
review for the analysis. A total of 78 drugs were reviewed by at least 2 agencies, 
producing a total of 195 reviews. RESULTS: There was generally a high level of 
agreement between all pairs of agencies, ranging from 56% (PBAC; CADTH) to 
91% (NICE; HAS). It is important to note that within the sample of drugs 
reviewed, all agencies issued positive recommendations at very high rates – all 
but CADTH issued positive recommendations for more than 80% of the drugs 
reviewed. This fact alone would produce high levels of agreement, even if 
agencies’ recommendations were statistically independent. Actual agreement 
rates observed were close to those implied by independence. CONCLUSIONS: 
Agencies agree on their reimbursement decisions quite often, but at rates close 
to those implied by their high overall positive recommendation rates alone. 
Future research will focus on identifying the determinants of agencies’ high 
rates of agreement.  
 
HT3  
ISSUES IN THE SELECTION OF COMPARATORS FOR REGULATORY AND HTA 
SUBMISSIONS  
DeLozier AM1, Murray JF1, Klopchin MN1, Johnston JA1, Grainger D2 
1Eli Lilly and Company, Indianapolis, IN, USA, 2Eli Lilly and Company USA /Australia, West 
Ryde, Australia  
